Dungarwalla, M <br/><br/>
Lack of clinical efficacy of rituximab in the treatment of autoimmune neutropenia and pure red cell aplasia: implications for their pathophysiology.  [electronic resource] 

 -  Annals of hematology  Mar 2007 
 - 191-7 p.  digital 
<br/><br/> Publication Type: Clinical Trial; Journal Article 
<br/><br/><label>ISSN: </label>1432-0584 
<br/><br/><label>Standard No.: </label>10.1007/s00277-006-0202-5  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Adult<br/>Aged<br/>Anemia, Hemolytic, Autoimmune--drug therapy<br/>Antibodies, Monoclonal--administration & dosage<br/>Antibodies, Monoclonal, Murine-Derived<br/>Bronchiectasis--chemically induced<br/>Drug Administration Routes<br/>Drug Administration Schedule<br/>Female<br/>Humans<br/>Immunologic Factors--administration & dosage<br/>Male<br/>Middle Aged<br/>Neutropenia--drug therapy<br/>Pilot Projects<br/>Pneumonia, Pneumocystis--chemically induced<br/>Purpura, Thrombocytopenic--drug therapy<br/>Red-Cell Aplasia, Pure--drug therapy<br/>Rituximab<br/>Time Factors<br/>Treatment Outcome